GlaxoSmithKline plc (GSK, GSK.L) and Innoviva, Inc. (INVA) announced Wednesday that IMPACT study shows significant benefits of Trelegy Ellipta in patients with chronic obstructive pulmonary disease (COPD) with a history of exacerbation.
from RTT - Biotech https://ift.tt/2JWnn9Y
via IFTTT
No comments:
Post a Comment